Legend Biotech (LEGN) Stock Forecast & Price Target

Compare

635 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LEGN Analyst Ratings

Strong Buy

9 Buy

2 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Legend

Biotech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LEGN Stock 12 Month Forecast

Average Price Target

$56.59

▲(186.52% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Legend Biotech in the last 3 months. The average price target is $56.59 with a high forecast of $80.00 and a low forecast of $21.00. The average price target represents a 186.52% change from the last price of $19.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","81":"$81","32.25":"$32.3","48.5":"$48.5","64.75":"$64.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.587272727272726,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$56.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,32.25,48.5,64.75,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.15,21.98461538461538,26.819230769230767,31.653846153846153,36.488461538461536,41.32307692307692,46.1576923076923,50.99230769230769,55.82692307692307,60.661538461538456,65.49615384615385,70.33076923076922,75.16538461538461,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.15,20.183636363636364,23.217272727272725,26.25090909090909,29.28454545454545,32.31818181818181,35.35181818181818,38.38545454545454,41.41909090909091,44.45272727272727,47.486363636363635,50.519999999999996,53.553636363636365,{"y":56.587272727272726,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.15,17.446153846153845,17.74230769230769,18.038461538461537,18.334615384615383,18.63076923076923,18.926923076923075,19.223076923076924,19.51923076923077,19.815384615384616,20.111538461538462,20.407692307692308,20.703846153846154,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.52,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.66,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$80.00

Average Price Target$56.59

Lowest Price Target$21.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mitchell Kapoor

H.C. Wainwright

$50

Buy

153.16%

Upside

Reiterated

02/24/26

Legend Biotech: Undervalued BCMA CAR-T Leader with Lower Commercial Risk and DCF-Supported Upside to $50 Target

Qize Ding

Rothschild & Co Redburn

$83→$24

Hold

21.52%

Upside

Downgraded

02/12/26

Legend Biotech downgraded to Neutral from Buy at Rothschild & Co RedburnLegend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn

Etzer Darout

Barclays

$80

Buy

305.06%

Upside

Reiterated

02/04/26

Legend Biotech (LEGN) Gets a Buy from Barclays

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

$65.6→$56.46

Buy

185.87%

Upside

Reiterated

01/22/26

Goldman Sachs Keeps Their Buy Rating on Legend Biotech (LEGN)

Yaron Werber

TD Cowen

$62→$21

Hold

6.33%

Upside

Downgraded

01/22/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Johnson & Johnson (NYSE: JNJ)

Kostas Biliouris

Oppenheimer

$75

Buy

279.75%

Upside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (NASDAQ: CRVS) and Legend Biotech (NASDAQ: LEGN)

Leonid Timashev

RBC Capital

$66

Buy

234.18%

Upside

Reiterated

01/20/26

FDA draft guidance favorable for Legend Biotech, says RBC CapitalFDA draft guidance favorable for Legend Biotech, says RBC Capital

Edward Tenthoff

Piper Sandler

$78

Buy

294.94%

Upside

Reiterated

01/15/26

Piper Sandler Remains a Buy on Legend Biotech (LEGN)

Eric Schmidt FCA

Cantor Fitzgerald

$75→$74

Buy

274.68%

Upside

Reiterated

12/17/25

Legend Biotech price target lowered to $74 from $75 at Cantor FitzgeraldLegend Biotech price target lowered to $74 from $75 at Cantor Fitzgerald

Terence Flynn

Morgan Stanley

$83→$50

Buy

153.16%

Upside

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Evommune, Inc. (NYSE: EVMN) and Eli Lilly & Co (NYSE: LLY)

Ashwani Verma

UBS

$54→$48

Buy

143.04%

Upside

Reiterated

12/08/25

Legend Biotech price target lowered to $48 from $54 at UBSLegend Biotech price target lowered to $48 from $54 at UBS

Asthika Goonewardene

Truist Financial

$71→$70

Buy

254.43%

Upside

Reiterated

11/13/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: HealthStream (NASDAQ: HSTM), Legend Biotech (NASDAQ: LEGN) and Immuneering (NASDAQ: IMRX)

Sami Corwin

William Blair

―

Hold

―

Reiterated

11/12/25

Legend Biotech's Strategic Growth and Risks: Analyst Assigns Hold Rating

Jessica Fye

J.P. Morgan

$78→$76

Buy

284.81%

Upside

Reiterated

10/09/25

J.P. Morgan Keeps Their Buy Rating on Legend Biotech (LEGN)

Justin Zelin

BTIG

$91

Buy

360.76%

Upside

Reiterated

08/11/25

Legend Biotech's Strategic Growth and Record Sales Drive Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mitchell Kapoor

H.C. Wainwright

$50

Buy

153.16%

Upside

Reiterated

02/24/26

Legend Biotech: Undervalued BCMA CAR-T Leader with Lower Commercial Risk and DCF-Supported Upside to $50 Target

Qize Ding

Rothschild & Co Redburn

$83→$24

Hold

21.52%

Upside

Downgraded

02/12/26

Legend Biotech downgraded to Neutral from Buy at Rothschild & Co RedburnLegend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn

Etzer Darout

Barclays

$80

Buy

305.06%

Upside

Reiterated

02/04/26

Legend Biotech (LEGN) Gets a Buy from Barclays

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

$65.6→$56.46

Buy

185.87%

Upside

Reiterated

01/22/26

Goldman Sachs Keeps Their Buy Rating on Legend Biotech (LEGN)

Yaron Werber

TD Cowen

$62→$21

Hold

6.33%

Upside

Downgraded

01/22/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Johnson & Johnson (NYSE: JNJ)

Kostas Biliouris

Oppenheimer

$75

Buy

279.75%

Upside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (NASDAQ: CRVS) and Legend Biotech (NASDAQ: LEGN)

Leonid Timashev

RBC Capital

$66

Buy

234.18%

Upside

Reiterated

01/20/26

FDA draft guidance favorable for Legend Biotech, says RBC CapitalFDA draft guidance favorable for Legend Biotech, says RBC Capital

Edward Tenthoff

Piper Sandler

$78

Buy

294.94%

Upside

Reiterated

01/15/26

Piper Sandler Remains a Buy on Legend Biotech (LEGN)

Eric Schmidt FCA

Cantor Fitzgerald

$75→$74

Buy

274.68%

Upside

Reiterated

12/17/25

Legend Biotech price target lowered to $74 from $75 at Cantor FitzgeraldLegend Biotech price target lowered to $74 from $75 at Cantor Fitzgerald

Terence Flynn

Morgan Stanley

$83→$50

Buy

153.16%

Upside

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Evommune, Inc. (NYSE: EVMN) and Eli Lilly & Co (NYSE: LLY)

Ashwani Verma

UBS

$54→$48

Buy

143.04%

Upside

Reiterated

12/08/25

Legend Biotech price target lowered to $48 from $54 at UBSLegend Biotech price target lowered to $48 from $54 at UBS

Asthika Goonewardene

Truist Financial

$71→$70

Buy

254.43%

Upside

Reiterated

11/13/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: HealthStream (NASDAQ: HSTM), Legend Biotech (NASDAQ: LEGN) and Immuneering (NASDAQ: IMRX)

Sami Corwin

William Blair

―

Hold

―

Reiterated

11/12/25

Legend Biotech's Strategic Growth and Risks: Analyst Assigns Hold Rating

Jessica Fye

J.P. Morgan

$78→$76

Buy

284.81%

Upside

Reiterated

10/09/25

J.P. Morgan Keeps Their Buy Rating on Legend Biotech (LEGN)

Justin Zelin

BTIG

$91

Buy

360.76%

Upside

Reiterated

08/11/25

Legend Biotech's Strategic Growth and Record Sales Drive Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Legend Biotech

3 Months

xxx

Success Rate

6/14 ratings generated profit

Average Return

+3.41%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +3.41% per trade.

1 Year

Justin ZelinBTIG

Success Rate

12/32 ratings generated profit

Average Return

-9.40%

a rating ―

Copying Justin Zelin's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -9.40% per trade.

2 Years

xxx

Success Rate

12/32 ratings generated profit

Average Return

-13.72%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -13.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LEGN Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LEGN has received 16 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. LEGN average Analyst price target in the past 3 months is 56.59.

Each month's total comprises the sum of three months' worth of ratings.

LEGN Financial Forecast

LEGN Earnings Forecast

Next quarter’s earnings estimate for LEGN is >-$0.01 with a range of -$0.19 to $0.58. The previous quarter’s EPS was -$0.11. LEGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year LEGN has Performed in-line its overall industry.

LEGN Sales Forecast

Next quarter’s sales forecast for LEGN is $307.32M with a range of $275.00M to $362.17M. The previous quarter’s sales results were $272.69M. LEGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year LEGN has Performed in-line its overall industry.

LEGN Stock Forecast FAQ

What is LEGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Legend Biotech Corporation’s 12-month average price target is 56.59.

What is LEGN’s upside potential, based on the analysts’ average price target?

Legend Biotech Corporation has 186.52% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LEGN a Buy, Sell or Hold?

Legend Biotech Corporation has a consensus rating of Strong Buy which is based on 9 buy ratings, 2 hold ratings and 0 sell ratings.

What is Legend Biotech Corporation’s price target?

The average price target for Legend Biotech Corporation is 56.59. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $21.00. The average price target represents 186.52% Increase from the current price of $19.75.

What do analysts say about Legend Biotech Corporation?

Legend Biotech Corporation’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of LEGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Legend Biotech (LEGN) Stock Forecast & Price Target

LEGN Analyst Ratings

LEGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Legend Biotech

LEGN Analyst Recommendation Trends

LEGN Financial Forecast

LEGN Earnings Forecast

LEGN Sales Forecast

LEGN Stock Forecast FAQ

Detailed List of Analyst Forecasts